IL160048A0 - Probiotic bifidobacterium strains - Google Patents
Probiotic bifidobacterium strainsInfo
- Publication number
- IL160048A0 IL160048A0 IL16004802A IL16004802A IL160048A0 IL 160048 A0 IL160048 A0 IL 160048A0 IL 16004802 A IL16004802 A IL 16004802A IL 16004802 A IL16004802 A IL 16004802A IL 160048 A0 IL160048 A0 IL 160048A0
- Authority
- IL
- Israel
- Prior art keywords
- bifidobacterium strains
- probiotic bifidobacterium
- probiotic
- strains
- bifidobacterium
- Prior art date
Links
- 241000186000 Bifidobacterium Species 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 230000000529 probiotic effect Effects 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/02—Acetobacter
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE20010710 | 2001-07-26 | ||
IE20010717 | 2001-07-26 | ||
IE20010714 | 2001-07-26 | ||
IE20010711 | 2001-07-26 | ||
IE20010709 | 2001-07-26 | ||
IE20010713 | 2001-07-26 | ||
PCT/IE2002/000110 WO2003010297A1 (en) | 2001-07-26 | 2002-07-26 | Probiotic bifidobacterium strains |
Publications (1)
Publication Number | Publication Date |
---|---|
IL160048A0 true IL160048A0 (en) | 2004-06-20 |
Family
ID=27547373
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16004802A IL160048A0 (en) | 2001-07-26 | 2002-07-26 | Probiotic bifidobacterium strains |
Country Status (12)
Country | Link |
---|---|
US (2) | US20030092163A1 (ja) |
EP (1) | EP1409644A1 (ja) |
JP (1) | JP2005508617A (ja) |
CN (1) | CN1561387A (ja) |
AU (1) | AU2002329006A1 (ja) |
BR (1) | BR0211442A (ja) |
CA (1) | CA2454803A1 (ja) |
IL (1) | IL160048A0 (ja) |
IN (1) | IN2004KO00093A (ja) |
MX (1) | MXPA04000738A (ja) |
PE (1) | PE20030284A1 (ja) |
WO (1) | WO2003010297A1 (ja) |
Families Citing this family (116)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8563522B2 (en) | 1997-07-08 | 2013-10-22 | The Iams Company | Method of maintaining and/or attenuating a decline in quality of life |
AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
US7182943B2 (en) * | 2002-05-15 | 2007-02-27 | UNIVERSITé LAVAL | Method and system for modulation of microbial cell characteristics |
SE526711C2 (sv) * | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
US20040197304A1 (en) | 2003-04-01 | 2004-10-07 | The Procter & Gamble Company And Alimentary Health, Ltd. | Methods of determining efficacy of treatments of inflammatory diseases of the bowel |
EP1664796B1 (en) * | 2003-09-15 | 2010-12-15 | Oklahoma Medical Research Foundation | Method of using cytokine assays to diagnose, treat, and evaluate ankylosing spondylitis |
WO2005030230A1 (en) * | 2003-09-30 | 2005-04-07 | Probiomics Limited | Compositions and methods for treatment or prevention of psoriasis and related disorders |
US8871266B2 (en) * | 2003-10-01 | 2014-10-28 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
AU2004275438B2 (en) * | 2003-10-01 | 2008-05-29 | Commonwealth Scientific & Industrial Research Organisation | Probiotic storage and delivery |
GB0323039D0 (en) * | 2003-10-01 | 2003-11-05 | Danisco | Method |
US20090257993A1 (en) | 2003-12-17 | 2009-10-15 | M Rabet Laura | Lactic Acid Producing Bacteria and Lung Function |
US7785635B1 (en) | 2003-12-19 | 2010-08-31 | The Procter & Gamble Company | Methods of use of probiotic lactobacilli for companion animals |
US20050158294A1 (en) | 2003-12-19 | 2005-07-21 | The Procter & Gamble Company | Canine probiotic Bifidobacteria pseudolongum |
US20050152884A1 (en) | 2003-12-19 | 2005-07-14 | The Procter & Gamble Company | Canine probiotic Bifidobacteria globosum |
US8894991B2 (en) | 2003-12-19 | 2014-11-25 | The Iams Company | Canine probiotic Lactobacilli |
US8877178B2 (en) | 2003-12-19 | 2014-11-04 | The Iams Company | Methods of use of probiotic bifidobacteria for companion animals |
WO2005072718A1 (ja) * | 2004-01-28 | 2005-08-11 | Kurume University | 乳清発酵物を含有する医薬組成物 |
JP2005247780A (ja) * | 2004-03-05 | 2005-09-15 | Masakazu Maruyama | ウイルス性肝炎治療剤 |
ES2262418B1 (es) * | 2004-12-28 | 2007-11-01 | Consejo Superior Investig. Cientificas | Extractos proteicos con amplio espectro de actividad antibacteriana y cepas del genero bifidobacterium que los producen. |
TW200700074A (en) * | 2005-03-04 | 2007-01-01 | Calpis Co Ltd | Inducer of t cell apoptosis |
WO2006097949A1 (en) * | 2005-03-16 | 2006-09-21 | Actial Farmacêutica, Lda. | Mixture of at least 6 species of lactic acid bacteria and/or bifidobacteria in the manufacture of sourdough |
AU2011205121B2 (en) * | 2005-04-08 | 2012-07-05 | Alimentary Health Ltd | Method of use of orally administered probiotic bifidobacteria for human beauty benefits |
US8926952B2 (en) | 2005-04-08 | 2015-01-06 | The Procter & Gamble Company | Methods of use of probiotic bifidobacteria for human beauty benefits |
JP2008539776A (ja) * | 2005-05-16 | 2008-11-20 | ユニベルシテ・ド・リエージュ | 共生ビフィドバクテリア種 |
DK1880001T3 (da) | 2005-05-31 | 2011-09-12 | Iams Company | Feline probiotiske lactobacilli |
CA2607949C (en) | 2005-05-31 | 2012-09-25 | Thomas William-Maxwell Boileau | Feline probiotic bifidobacteria |
EP1967196A4 (en) | 2005-11-18 | 2009-10-14 | Idemitsu Kosan Co | CONTROL AGENT OF A TOXIC BACTERIUM CONTAINING BACILLUS THURINGIENSIS |
GB0524103D0 (en) | 2005-11-26 | 2006-01-04 | Medical Res Council | Healing |
US7943328B1 (en) | 2006-03-03 | 2011-05-17 | Prometheus Laboratories Inc. | Method and system for assisting in diagnosing irritable bowel syndrome |
ATE552734T1 (de) | 2006-03-31 | 2012-04-15 | Morinaga Milk Industry Co Ltd | Verfahren zur herstellung des interleukin- produktionsreglers |
US20100094560A1 (en) * | 2006-08-15 | 2010-04-15 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
US20080085524A1 (en) * | 2006-08-15 | 2008-04-10 | Prometheus Laboratories Inc. | Methods for diagnosing irritable bowel syndrome |
WO2008053444A2 (en) * | 2006-11-01 | 2008-05-08 | The Procter & Gamble Company | Treating a respiratory condition with bifidobacterium |
CA2675729C (en) | 2007-01-17 | 2015-05-12 | Meiji Dairies Corporation | Prophylactic and/or therapeutic agent for functional gastrointestinal disorders |
AU2008211600B8 (en) | 2007-02-01 | 2014-02-13 | Mars, Incorporated | Method for decreasing inflammation and stress in a mammal using glucose antimetabolites, avocado or avocado extracts |
EP2114423B2 (en) * | 2007-02-28 | 2020-01-01 | MJN U.S. Holdings LLC | Inactivated lactobacillus rhammosus gg for treating systemic inflammation in infants |
KR20090127180A (ko) * | 2007-03-28 | 2009-12-09 | 앨러멘터리 헬스 리미티드 | 프로바이오틱 비피도박테리움 스트레인 |
EP2134833B1 (en) | 2007-03-28 | 2016-03-09 | Alimentary Health Limited | Probiotic bifidobacterium strain |
ES2578261T3 (es) | 2007-05-18 | 2016-07-22 | Nestec S.A. | Lactobacillus johnsonii para prevenir infecciones postoperatorias |
ES2523575T3 (es) | 2007-06-27 | 2014-11-27 | Laboratorios Ordesa, S.L. | Una nueva cepa de bifidobacterium y peptidos acitvos contra infecciones por rotavirus |
EP2065048A1 (en) * | 2007-11-30 | 2009-06-03 | Institut Pasteur | Use of a L. casei strain, for the preparation of a composition for inhibiting mast cell activation |
ES2343499B1 (es) * | 2007-12-24 | 2011-06-10 | Consejo Superior De Investigaciones Cientificas | Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten. |
US9771199B2 (en) | 2008-07-07 | 2017-09-26 | Mars, Incorporated | Probiotic supplement, process for making, and packaging |
US20110189149A1 (en) * | 2008-06-20 | 2011-08-04 | Remy Burcelin | New Uses of Lactic Acid Bacteria and Bifidobacteria |
BRPI1014081A2 (pt) * | 2009-06-19 | 2016-04-19 | Danisco | uso de uma bactéria da espécie bifidobacterium animalis subsp lactis cepa 420 (b420) ou uma mistura da mesma |
US10104903B2 (en) | 2009-07-31 | 2018-10-23 | Mars, Incorporated | Animal food and its appearance |
ES2664828T3 (es) * | 2009-08-25 | 2018-04-23 | Nestec S.A. | Bifidobacterium longum y trastornos GI funcionales |
WO2011044516A2 (en) * | 2009-10-09 | 2011-04-14 | Prothera, Inc. | Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease |
WO2011058535A1 (en) * | 2009-11-11 | 2011-05-19 | Alimentary Health Limited | Probiotic bifidobacterium strain |
WO2011148219A1 (en) | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving the enteric nervous system |
WO2011148220A1 (en) | 2010-05-28 | 2011-12-01 | Compagnie Gervais Danone | Probiotic strains for use in improving transepithelial resistance |
NZ607043A (en) | 2010-08-04 | 2015-05-29 | Borody Thomas J | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
US9011909B2 (en) | 2010-09-03 | 2015-04-21 | Wisconsin Pharmacal Company, Llc | Prebiotic suppositories |
ES2389547B1 (es) * | 2010-12-07 | 2013-08-08 | Consejo Superior De Investigaciones Científicas (Csic) | Bifidobacterium cect 7765 y su uso en la prevención y/o tratamiento del sobrepeso, la obesidad y patologías asociadas. |
US9408878B2 (en) | 2010-12-17 | 2016-08-09 | Compagnie Gervais Danone | Lactococcus lactis strains for use in improving digestive condition |
WO2012122478A1 (en) | 2011-03-09 | 2012-09-13 | Regents Of The University Of Minnesota | Compositions and methods for transplantation of colon microbiota |
CN102899261B (zh) * | 2011-03-11 | 2016-12-07 | 光晟生物科技股份有限公司 | 长双歧杆菌长亚种br022菌株的用途 |
GB201112091D0 (en) | 2011-07-14 | 2011-08-31 | Gt Biolog Ltd | Bacterial strains isolated from pigs |
GB201117313D0 (en) | 2011-10-07 | 2011-11-16 | Gt Biolog Ltd | Bacterium for use in medicine |
AU2013235340B2 (en) * | 2012-03-17 | 2019-05-23 | The Regents Of The University Of California | Fast diagnosis and personalized treatments for acne |
US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
GB201306536D0 (en) | 2013-04-10 | 2013-05-22 | Gt Biolog Ltd | Polypeptide and immune modulation |
ITMI20131467A1 (it) | 2013-09-06 | 2015-03-07 | Sofar Spa | Uso di una composizione comprendente microrganismi per aumentare la produzione intestinale di acido butirrico, di acido folico o di niacina e/o per diminuire la produzione intestinale di acido succinico |
JP6431080B2 (ja) | 2014-01-24 | 2018-11-28 | ザ プロクター アンド ギャンブル カンパニー | 微生物を含むフィラメント及びその作製方法 |
US20150209468A1 (en) | 2014-01-24 | 2015-07-30 | The Procter & Gamble Company | Hygiene article containing microorganism |
WO2015112292A1 (en) | 2014-01-24 | 2015-07-30 | The Procter & Gamble Company | Web comprising a microorganism-containing fibrous element and method for making same |
MA39710A (fr) | 2014-04-23 | 2015-10-29 | Sofar Spa | Composition topique destinée à être utilisée dans le traitement d'une maladie inflammatoire de l'intestin |
SG11201704811YA (en) * | 2014-12-23 | 2017-07-28 | 4D Pharma Res Ltd | Immune modulation |
BR112017013274A2 (pt) | 2014-12-23 | 2018-02-06 | 4D Pharma Research Limited | polipeptídeo e imunomodulação |
MX2017014488A (es) | 2015-05-14 | 2018-06-11 | Crestovo Holdings Llc | Composiciones para transplante de la flora fecal y metodos para elaborarlos y utilizarlos y dispositivos para suministrarlos. |
DK3297644T3 (da) | 2015-05-22 | 2022-04-11 | Univ Arizona State | Fremgangsmåder til behandling af autismespektrumforstyrrelse og forbundne symptomer |
US20160354507A1 (en) | 2015-06-07 | 2016-12-08 | The Procter & Gamble Company | Article of commerce containing absorbent article |
CN115364122A (zh) | 2015-06-15 | 2022-11-22 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
SI3307288T1 (sl) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Spojine, ki vsebujejo bakterijske seve |
NZ737752A (en) | 2015-06-15 | 2022-02-25 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
MA41060B1 (fr) | 2015-06-15 | 2019-11-29 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
MA41010B1 (fr) | 2015-06-15 | 2020-01-31 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
US20170020750A1 (en) | 2015-07-23 | 2017-01-26 | The Procter & Gamble Company | Patch containing microorganism |
GB201520497D0 (en) | 2015-11-20 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
CN112569262A (zh) | 2015-11-20 | 2021-03-30 | 4D制药研究有限公司 | 包含细菌菌株的组合物 |
GB201520638D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201520631D0 (en) | 2015-11-23 | 2016-01-06 | 4D Pharma Res Ltd | Compositions comprising bacterial strains |
GB201612191D0 (en) | 2016-07-13 | 2016-08-24 | 4D Pharma Plc | Compositions comprising bacterial strains |
CN108883139B (zh) | 2016-03-04 | 2022-04-26 | 4D制药有限公司 | 包含细菌菌株的组合物 |
CA3021793A1 (en) | 2016-04-21 | 2017-10-26 | Naked Biome, Inc. | Compositions and methods for treatment of skin disorders |
MA45327A (fr) | 2016-05-13 | 2019-03-20 | Sofar Spa | Utilisation de probiotiques pour améliorer l'absorption des protéines |
MA45288A (fr) | 2016-06-08 | 2019-04-17 | Sofar Spa | Nouvelle utilisation médicale de probiotiques |
US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
TW201821093A (zh) | 2016-07-13 | 2018-06-16 | 英商4D製藥有限公司 | 包含細菌菌株之組合物 |
US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11026978B2 (en) | 2016-10-11 | 2021-06-08 | Finch Therapeutics Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
IT201600122724A1 (it) | 2016-12-02 | 2018-06-02 | Sofar Spa | Exopolysaccharides and uses thereof |
GB201621123D0 (en) | 2016-12-12 | 2017-01-25 | 4D Pharma Plc | Compositions comprising bacterial strains |
IT201600127498A1 (it) | 2016-12-16 | 2018-06-16 | Sofar Spa | Probiotici per uso nella diverticolosi e malattia diverticolare |
US11590179B2 (en) | 2017-02-28 | 2023-02-28 | Precisionbiotics Group Limited | Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection |
DK3532603T3 (da) * | 2017-02-28 | 2020-12-07 | Prec Group Limited | Bifidobacterium longum til fordelagtig modulation af immunrespons på respiratorisk virusinfektion |
CA3058818A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating parkinson's disease (pd) and related disorders |
WO2018187464A1 (en) | 2017-04-05 | 2018-10-11 | Crestovo Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
MA48939B1 (fr) | 2017-05-22 | 2021-06-30 | 4D Pharma Res Ltd | Compositions comprenant des souches bactériennes |
EP3630942B1 (en) | 2017-05-24 | 2022-11-30 | 4D Pharma Research Limited | Compositions comprising bacterial strain |
AU2018272048B2 (en) | 2017-05-26 | 2024-04-04 | Finch Therapeutics Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
RS61210B1 (sr) | 2017-06-14 | 2021-01-29 | 4D Pharma Res Ltd | Kompozicije koje sadrže bakterijske sojeve |
JP6837581B2 (ja) | 2017-06-14 | 2021-03-03 | フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited | Megasphaera属の細菌株を含む組成物及びその使用 |
AR112328A1 (es) | 2017-07-05 | 2019-10-16 | Evelo Biosciences Inc | Composiciones y métodos para tratamiento de cáncer usando bifidobacterium animalis ssp. lactis |
CA3072032A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | Compositions and methods for maintaining and restoring a healthy gut barrier |
JP7280069B2 (ja) * | 2018-03-28 | 2023-05-23 | 森永乳業株式会社 | 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物 |
CN115058368A (zh) * | 2018-05-10 | 2022-09-16 | 苏州博悦曼环保科技有限公司 | 一种复合菌剂在降解餐厨垃圾中的应用及一种高效降解餐厨垃圾的复合菌剂制造方法 |
US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
KR20210065969A (ko) | 2018-09-27 | 2021-06-04 | 핀치 테라퓨틱스 홀딩스 엘엘씨 | 간질 및 관련 장애를 치료하기 위한 조성물 및 방법 |
CN109929773B (zh) * | 2019-01-10 | 2020-06-19 | 江苏德禧生物科技有限公司 | 一株可用于富硒培养的双歧杆菌及其活性蛋白和应用 |
CN110218710B (zh) * | 2019-04-30 | 2020-06-23 | 中国科学院天津工业生物技术研究所 | 活性提高的磷酸转酮酶及在生产代谢物中的应用 |
US11751597B2 (en) | 2019-11-05 | 2023-09-12 | Alfasigma S.P.A. | Compositions comprising bacterial strains for use in increasing the bioavailability of amino acids derived from proteins, and related food product methods and systems |
CN116083327B (zh) * | 2023-04-07 | 2023-06-09 | 天赋能(天津)功能食品研究发展有限公司 | 长双歧杆菌婴儿亚种及在缓解便秘、抗结肠组织炎症和改善肠道菌群方面的应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5902578A (en) * | 1996-03-25 | 1999-05-11 | Abbott Laboratories | Method and formula for the prevention of diarrhea |
US5902743A (en) * | 1998-03-20 | 1999-05-11 | Wisconsin Alumni Research Foundation | Probiotic bifidobacterium strain |
ID29150A (id) * | 1999-01-15 | 2001-08-02 | Entpr Ireland Cs | Penggunaan lactobacillus salivarius |
-
2002
- 2002-07-25 PE PE2002000664A patent/PE20030284A1/es not_active Application Discontinuation
- 2002-07-25 US US10/201,940 patent/US20030092163A1/en not_active Abandoned
- 2002-07-26 IL IL16004802A patent/IL160048A0/xx unknown
- 2002-07-26 AU AU2002329006A patent/AU2002329006A1/en not_active Abandoned
- 2002-07-26 CA CA002454803A patent/CA2454803A1/en not_active Abandoned
- 2002-07-26 CN CNA028185773A patent/CN1561387A/zh active Pending
- 2002-07-26 BR BR0211442-9A patent/BR0211442A/pt not_active IP Right Cessation
- 2002-07-26 WO PCT/IE2002/000110 patent/WO2003010297A1/en not_active Application Discontinuation
- 2002-07-26 JP JP2003515648A patent/JP2005508617A/ja not_active Withdrawn
- 2002-07-26 EP EP02765292A patent/EP1409644A1/en not_active Withdrawn
- 2002-07-26 MX MXPA04000738A patent/MXPA04000738A/es not_active Application Discontinuation
-
2004
- 2004-01-27 IN IN93KO2004 patent/IN2004KO00093A/en unknown
-
2005
- 2005-06-10 US US11/149,195 patent/US20060121015A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2005508617A (ja) | 2005-04-07 |
MXPA04000738A (es) | 2004-07-08 |
US20030092163A1 (en) | 2003-05-15 |
WO2003010297A1 (en) | 2003-02-06 |
BR0211442A (pt) | 2004-11-09 |
PE20030284A1 (es) | 2003-05-01 |
CA2454803A1 (en) | 2003-02-06 |
CN1561387A (zh) | 2005-01-05 |
IN2004KO00093A (ja) | 2006-03-03 |
EP1409644A1 (en) | 2004-04-21 |
AU2002329006A1 (en) | 2003-02-17 |
US20060121015A1 (en) | 2006-06-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL160048A0 (en) | Probiotic bifidobacterium strains | |
IL160050A0 (en) | Probiotic lactobacillus casei strains | |
AU7616001A (en) | Probiotic recolonisation therapy | |
AU2003265296A8 (en) | Lactobacillus strains and uses therefor | |
HUP0401017A3 (en) | Combination of probiotics | |
AU2002351623A8 (en) | Streptococcus antigens | |
EP1718154A4 (en) | PROBIOTIC DOG LACTOBACILLA | |
IL173692A0 (en) | Bacterial strains, compositions including same and probiotic use thereof | |
ZA200410399B (en) | Probiotics and oral tolerance. | |
AU6079201A (en) | Lactobacillus reuteri glucosyltransferase | |
EP1527159A4 (en) | PROBIOTIC PROPIONIBACTERIUM JENSENII 702 | |
EP1450610A4 (en) | PROBIOTIC COMPOSITIONS | |
AU2002355284A8 (en) | Direct-fed microbial | |
AU2003250503A8 (en) | Probiotic therapies using lactobacillus reuteri | |
ZA200407456B (en) | Lactobacillus strains. | |
AU2003225362A1 (en) | Lactobacillus acidophilus ky1909 | |
PL362753A1 (en) | New strain of lactobacillus paracasei | |
GB2370770B (en) | Uses of Streptococcus Vaccines | |
AU2002312624A8 (en) | Drug metabolizing enzymes | |
PL354667A1 (en) | Probiotic preparation | |
AU2003284240A8 (en) | Probiotic bacteria | |
AU2002217608A1 (en) | Novel lactobacillus reuteri useful as probiotics | |
GB2372248B (en) | Kiln furniture | |
SG97174A1 (en) | Lactobacillus rhamnosus strain and uses thereof | |
GB0118723D0 (en) | TSE probiotic 3 |